|
| Inflammation measures ( = 295) | |
| CRP (mg/L), median iqr | 1.1 2.0 |
| IL-6 (pg/mL), median iqr | 2.0 1.5 |
| TNFα (pg/mL), mean sd | 9.0 2.9 |
| PAI-1 (ng/mL), mean sd | 47 26 |
| Adiponectin (μg/mL), median iqr | 9.0 7.7 |
|
| Insulin sensitivity/resistance ( = 293) | |
| Glucose (mg/dL), mean sd | 95 8 |
| Diabetes status, (%) | |
| Normal (glucose < 100) | 219 (75) |
| Prediabetic (glucose 100–125) | 74 (25) |
| HOMA, median iqr | 1.1 0.8 |
| QUICKI, mean sd | 0.37 0.03 |
|
| Microvascular measures ( = 254) | |
| Capillary density: at rest (# capillaries per mm2), mean sd | 37 8 |
| Capillary density: venous occlusion (# capillaries per mm2), mean sd | 55 12 |
|
| Urine albumin excretion ( = 250) | |
| Albumin (μg/mL), median iqr | 1.9 2.6 |
| Albumin (μg/min), median iqr | 1.4 1.9 |
| Albumin-to-creatinine ratio (ACR, mg/g), median iqr | 2.8 3.8 |
|
| Endothelial measures ( = 271) | |
| FBF postischemic, mean sd | 27 9 |
| FBF ratio (postischemic to baseline), mean sd | 9 3 |
| FBF increase from baseline to postischemic (%), mean sd | 795 330 |
| FVR postischemic, median iqr | 2.9 1.4 |
| FVR ratio (baseline to postischemic), median iqr | 0.12 0.07 |
| FVR decrease from baseline to postischemic (%), mean sd | 87 6 |
|